We have located links that may give you full text access.
[Supplementation with high-dose L-carnitine on hemodialysis tolerance in uremic patients with severe heart diseases].
Zhonghua Yi Xue za Zhi [Chinese medical journal] 2017 December 27
Objective: To investigate the effect of intravenous supplementation with high-dose L-carnitinen on hemodialysis tolerance in uremic patients with severe heart disease (ischemic heart disease, congestive heart disease and arrhythmia). Methods: Between March 2012 and March 2017, 5 gram L-carnitine was given after the completion of each hemodialysis treatment (3-4 times a week) over a period of two weeks in 29 maintenance hemodialysis patients with severe heart diseases manifested by frequently symptomatic hypotension, chest tightness, wheezing, palpitation, chest pain and other symptoms during hemodialysis. The hemodialysis duration, heart functional classification (New York Heart Association Functional Classification, NYHA ), blood pressure and arrhythmia were analyzed before and after the treatment. Results: The duration of hemodialysis was significantly prolonged after treatment [from 2.0-3.5 (2.6±0.4)h to 3.0-4.0 (3.8±0.4) h, t =10.66, P <0.01]. Cardiac function was improved ( Z =-4.74, P <0.01). The hypotension and arrhythmia during dialysis was improved. Conclusion: High-dose of intravenous L-carnitine supplementation can improve hemodialysis tolerance and the symptoms of heart failure, arrhythmia, ischemic cardiac disease in hemodialysis patients with severe heart diseases.
Full text links
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app